Theravance : Clinical Results in the LAMA Respiratory Program for the Treatment of COPD

July 14, 2008 - Theravance, Inc. (NASDAQ: THRX) announced the results from a Phase 1 study designed to assess the safety, tolerability and pharmacokinetics of an investigational inhaled long-acting muscarinic antagonist (LAMA), GSK1160724/TD-4208 (TD-4208), for the treatment of chronic obstructive pulmonary disease (COPD). In this study, TD-4208 was generally well tolerated at all doses tested. In addition, TD-4208 showed the potential for 24-hour bronchodilation in COPD patients.

Originally discovered by Theravance, TD-4208 was licensed to GlaxoSmithKline (GSK) in 2004 under the terms of the companies' Strategic Alliance Agreement. Recently, GSK informed Theravance that it intends to return the LAMA program to Theravance because the current formulation of TD-4208 is incompatible with GSK's proprietary inhaler device.

Both parties are currently discussing the transfer of information and materials back to Theravance... Theravance's Press Release -

GlaxoSmithKline and Theravance, 642444 and 685698 advance in clinical development for the treatment of asthma

Jan. 03, 2008 - GlaxoSmithKline Plc (GSK) and Theravance, Inc. (NASDAQ: THRX) announced the start of large Phase 2b asthma dose-optimisation studies with both the lead inhaled corticosteroid (ICS) GW685698 ('698) and the lead long-acting beta agonist (LABA) GW642444 ('444) assets in the 'Horizon' programme to develop a next-generation combination product. GSK began enrolling patients with mild to severe asthma in the '698 Phase 2b clinical programme on 21st December 2007 and began enrolling patients with persistent asthma in the '444 Phase 2b clinical programme on 29th December 2007. These clinical programmes will determine the most effective doses to be taken into Phase 3 combination studies. The Phase 2b COPD programme with '444 is also on schedule to commence in 1H 2008... GSK's Press Release - Theravance's Press Release-

Theravance, GSK1160724, Phase 1 Clinical Study With Investigational Medicine For Respiratory Disease

December 12, 2007 - Theravance, Inc. (NASDAQ: THRX) announced that GlaxoSmithKline plc (GSK) initiated subject screening in a Phase 1 clinical study designed to assess the safety, tolerability, and pharmacokinetics of an investigational, inhaled bronchodilator, GSK1160724, for the treatment of chronic obstructive pulmonary disease (COPD)...GSK1160724 is an inhaled, long-acting muscarinic antagonist (LAMA) discovered by Theravance through the application of multivalent drug design in a drug discovery program dedicated to finding new medicines for respiratory diseases such as COPD and asthma... Theravance's Press Release -

Theravance, Initiation of Phase 2 Clinical Program with its MABA Compound in COPD

October 31, 2007 - Theravance, Inc. (NASDAQ: THRX) announced that GSK has initiated a Phase 2 clinical study of GSK961081, an investigational bifunctional muscarinic antagonist-beta₂ agonist compound for the treatment of chronic obstructive pulmonary disease (COPD)... Theravance's Press Release -